Upheaval at Imclone (IMCL, BMY, AMGN, ABGX)

Back in November, we posted a piece discussing the merits of Amgen’s (ticker: AMGN) and Abgenix’s (ticker: ABGX) panitumumab in treating colorectal cancer and the negative implications for Bristol-Myers’ (ticker: BMY) and Imclone’s (ticker: IMCL) Erbitux. The post incited considerable emotion, and many people adamantly disagreed with the conclusion – “Erbitux is in big trouble.